

I CLAIM:

- 1           1. A method for prevention of graft rejection in a lung transplant recipient  
2 comprising administering to the recipient an effective dose of aerosolized cyclosporine directly  
3 following transplantation in an amount sufficient to prevent graft rejection.
- 4           2. The method of claim 1 wherein the dose of cyclosporine is sufficient  
5 to achieve deposition levels ranging between 15 and 30 mg in the lung.
- 6           3. The method of claim 1 wherein the cyclosporine is co-administered with  
7 a second immunosuppressive agent.
- 8           4. The method of claim 1 wherein the cyclosporine is co-administered with a  
9 anti-inflammatory reagent.
- 1           5. A method for ameliorating pulmonary inflammation in a subject  
2 comprising administering to the subject an amount of aerosolized cyclosporine effective to  
3 inhibit or ameliorate pulmonary inflammation.
- 4           6. The method of claim 5 wherein the pulmonary inflammation is associated  
5 with asthma, sarcoidosis, emphysema, cystic fibrosis, idiopathic pulmonary fibrosis, chronic  
6 bronchitis, or allergic rhinitis.

7                    7.     The method of claim 5 wherein the dose of cyclosporine is sufficient  
8 to achieve deposition levels ranging between 5 and 30 mg in the lung.

9                    ~~8.~~     A method for prevention of graft rejection in a non-lung transplant  
10 recipient comprising administering to the non-lung transplant recipient an effective dose of  
11 aerosolized cyclosporine in an amount sufficient to prevent graft rejection.

12                    9.     The method of claim 8 wherein the dose of cyclosporine is sufficient to  
13 achieve circulating levels ranging between 50-250 ng/ml.

14                    10.    The method of claim 8 wherein the cyclosporine is co-administered with a  
15 second immunosuppressive agent.

16                    ~~11.~~    A method for inhibiting the immune response associated with a T-cell  
17 mediated immune disorder in a subject comprising the administering to the subject an amount of  
18 cyclosporine effective to inhibit the immune response associated with the immune disorder.

19  
20                    ~~12.~~    A composition comprising a suitable carrier and aerosolized  
21 cyclosporine in doses sufficient to reduce pulmonary inflammation in subjects having pulmonary  
22 disorders.

23 13. The composition of claim 12 wherein the aerosolized cyclosporine has a  
24 particle size of between 1 and 5 microns.

25 14. The composition of Claim 12 wherein the dose is sufficient to achieve  
26 concentration levels of between 5-15 mg of cyclosporine in the lung.

27 15. The composition of Claim 12 wherein the carrier is propylene glycol.

28 16. A composition comprising aerosolized cyclosporine as a dry powder,  
29 having a particle size in the range between 1 and 5 microns.

30 17. A composition comprising a suitable carrier and aerosolized cyclosporine  
31 in doses sufficient to prevent development of an immune response that would lead to graft  
32 rejection in a transplant recipient.

33 18. The composition of claim 17 wherein the cyclosporine has a particle size  
34 of between .1 and 2 microns.

35